JPH03209309A - Alopecia-preventing agent - Google Patents
Alopecia-preventing agentInfo
- Publication number
- JPH03209309A JPH03209309A JP2003239A JP323990A JPH03209309A JP H03209309 A JPH03209309 A JP H03209309A JP 2003239 A JP2003239 A JP 2003239A JP 323990 A JP323990 A JP 323990A JP H03209309 A JPH03209309 A JP H03209309A
- Authority
- JP
- Japan
- Prior art keywords
- hair
- alopecia
- extract
- horsetail
- horsetail extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000004384 Alopecia Diseases 0.000 title abstract description 96
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 90
- 239000000284 extract Substances 0.000 claims abstract description 86
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 230000003658 preventing hair loss Effects 0.000 claims description 26
- 210000004209 hair Anatomy 0.000 abstract description 138
- 231100000360 alopecia Toxicity 0.000 abstract description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 41
- 239000003795 chemical substances by application Substances 0.000 abstract description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 29
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract description 16
- 239000007788 liquid Substances 0.000 abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract description 12
- 230000012010 growth Effects 0.000 abstract description 8
- 239000000843 powder Substances 0.000 abstract description 8
- 239000000203 mixture Substances 0.000 abstract description 7
- 235000011187 glycerol Nutrition 0.000 abstract description 6
- 235000019486 Sunflower oil Nutrition 0.000 abstract description 5
- 239000006071 cream Substances 0.000 abstract description 5
- 239000002600 sunflower oil Substances 0.000 abstract description 5
- 208000003024 Diffuse alopecia Diseases 0.000 abstract description 4
- 241000195950 Equisetum arvense Species 0.000 abstract description 2
- 239000005768 Equisetum arvense L. Substances 0.000 abstract description 2
- 239000000443 aerosol Substances 0.000 abstract description 2
- 239000000839 emulsion Substances 0.000 abstract description 2
- 125000005456 glyceride group Chemical group 0.000 abstract description 2
- 244000025254 Cannabis sativa Species 0.000 abstract 1
- 244000061944 Helianthus giganteus Species 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 230000003698 anagen phase Effects 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 20
- 230000003676 hair loss Effects 0.000 description 20
- 208000024963 hair loss Diseases 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 230000003656 anti-hair-loss Effects 0.000 description 16
- 239000002904 solvent Substances 0.000 description 14
- 230000003797 telogen phase Effects 0.000 description 14
- 239000002537 cosmetic Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 238000000605 extraction Methods 0.000 description 9
- 239000003205 fragrance Substances 0.000 description 8
- 229940088597 hormone Drugs 0.000 description 8
- 239000005556 hormone Substances 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 235000015961 tonic Nutrition 0.000 description 8
- 230000001256 tonic effect Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000001973 epigenetic effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 239000003960 organic solvent Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 206010068168 androgenetic alopecia Diseases 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 210000000416 exudates and transudate Anatomy 0.000 description 5
- 239000003676 hair preparation Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 208000004631 alopecia areata Diseases 0.000 description 4
- 201000002996 androgenic alopecia Diseases 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 230000031774 hair cycle Effects 0.000 description 4
- 210000004919 hair shaft Anatomy 0.000 description 4
- 239000012676 herbal extract Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 229940058015 1,3-butylene glycol Drugs 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003779 hair growth Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000016507 interphase Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 229960000716 tonics Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- 244000085625 Equisetum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 240000007313 Tilia cordata Species 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000013022 formulation composition Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000000118 hair dye Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- -1 polyoxyethylene Polymers 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 201000001297 telogen effluvium Diseases 0.000 description 2
- BKVIYDNLLOSFOA-UHFFFAOYSA-N thallium Chemical compound [Tl] BKVIYDNLLOSFOA-UHFFFAOYSA-N 0.000 description 2
- 229910052716 thallium Inorganic materials 0.000 description 2
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 2
- 229960003053 thiamphenicol Drugs 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 208000006413 Digital Dermatitis Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000758993 Equisetidae Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 229920001499 Heparinoid Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 208000000038 Hypoparathyroidism Diseases 0.000 description 1
- 206010021067 Hypopituitarism Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000039951 Lithocarpus glaber Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 244000058602 Pisum arvense Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000017276 Salvia Nutrition 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003200 antithyroid agent Substances 0.000 description 1
- 229940043671 antithyroid preparations Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000023867 digital dermatitis in cattle Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000002554 heparinoid Substances 0.000 description 1
- 229940025770 heparinoids Drugs 0.000 description 1
- 201000006122 hypervitaminosis A Diseases 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000005201 scrubbing Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 229950000329 thiouracil Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【発明の詳細な説明】
〈産業上の利用分野〉
この発明は、毛髪(頭髪・眉毛・髭・賛など)の脱毛防
止剤に関する発明である。さらに詳しくは、この発明は
休止期上性脱毛症、成長期上性脱毛症など広範囲の各種
脱毛症に対して顕著な脱毛防止効果を奏する脱毛防止剤
に関するものである〈従来の技術および発明の背景〉
従来から体毛には毛周期(ヘアサイクル)があることが
知られている。すなわち、毛乳頭から短くて細い毛幹が
出始めた早期成長期毛〔うぶ毛の段階〕が発毛し始める
と、次第に毛球(毛根)は大きくなり毛幹も太くなって
ゆき中期成長期毛をつくる。さらに、この中期成長期毛
が進むと後期成長期毛ができ、この後期成長期毛の毛根
は皮下組織にまで達し、毛幹は我々が日常見ている毛と
なる。この後期成長期毛は数年(−船釣に毛の寿命は男
性の場合約2〜5年1女性の場合約4〜6年といわれて
いるが、それ以上伸び続ける人もいる)を経ると、寿命
がきて毛球部(毛根部)から角化し始め9その角化し始
める初めの段階を移行期毛といい、この移行期毛は、ま
だ完全に角化せず約2週間で次の休止期毛になってゆ(
、そして、この休止期毛の毛球(毛根)は完全に角化し
て毛幹は次第に表面に押し上げられ脱毛する。この際毛
乳頭部にあった結合組織は小さくなりながらも毛包に付
着していて、これが新しい早期成長期毛〔前記うぶ毛〕
の結合組織性の毛乳頭となってゆく、これらの毛周期に
よる毛根の変化はすべて毛の変動部で行われており、脂
腺開口部から上の方は変化しないといわれている。[Detailed Description of the Invention] <Industrial Application Field> This invention relates to an agent for preventing hair loss (head hair, eyebrows, beards, hair, etc.). More specifically, the present invention relates to a hair loss prevention agent that exhibits a remarkable hair loss prevention effect on a wide variety of alopecias such as telogen epigenetic alopecia and anagen epigenetic alopecia. Background> It has long been known that body hair has a hair cycle. In other words, when the early anagen hair (down hair stage), in which a short, thin hair shaft begins to emerge from the dermal papilla, begins to grow, the hair bulb (hair root) gradually becomes larger and the hair shaft becomes thicker, leading to the middle anagen stage. Create hair. Furthermore, as this mid-anagen hair progresses, late anagen hair is formed, and the roots of this late anagen hair reach the subcutaneous tissue, and the hair shaft becomes the hair we see every day. This late anagen hair grows over several years (it is said that the lifespan of hair in boat fishing is about 2 to 5 years for men, and about 4 to 6 years for women, but some people continue to grow longer). At the end of its lifespan, the hair bulb (hair root) begins to keratinize.9 The first stage of keratinization is called transitional hair, and this transitional hair has not yet completely keratinized and in about 2 weeks, the next hair begins to keratinate. The hair has become telogen (
Then, the hair bulb (hair root) of this telogen hair becomes completely keratinized, and the hair shaft is gradually pushed up to the surface and hair is removed. At this time, the connective tissue that was in the dermal papilla becomes smaller but still attaches to the hair follicle, and this becomes the new early growth hair [the downy hair mentioned above].
It is said that all changes in the hair root during the hair cycle, which lead to the formation of connective tissue dermal papillae, take place in the fluctuating part of the hair, and that the area above the sebaceous gland opening remains unchanged.
ひと口に脱毛症といっても、その原因は内因性のものや
外因性のものなど数多くの疾患があり、さらに内因性の
ものでも脱毛を主訴としてくる場合や、原疾患の一症状
として脱毛が現れている場合などがある。Although alopecia is simply called alopecia, it can be caused by many diseases, both endogenous and extrinsic.Furthermore, even if the cause is endogenous, hair loss may be the main complaint, or hair loss may be a symptom of the underlying disease. There are cases where it appears.
脱毛症は大別して、■休止期上性脱毛症の病気(基本的
に成長期毛の毛根の角化し始めた休止期毛が抜は毛とし
て沢山抜ける病気)と、■生長期毛性脱毛症の病気(基
本的に成長期毛の毛根の破壊された萎縮毛が抜は毛とし
て沢山抜ける病気)とに区別できる。もとより、前記休
止期性脱毛症においても抜は毛に萎縮毛が混ざって抜け
てくる場合もあり、また前記成長期上性脱毛症において
も抜は毛に休止期毛が混ざってくる場合もあり、単に抜
は毛の種類によって前記■休止期上性脱毛症と■成長期
性脱毛症とを明確に区別できない。Alopecia can be broadly divided into ■ Telogen epigenetic alopecia (a disease in which a large amount of telogen hair, in which the root of the anagen hair begins to keratinate, falls out as hair) and ■ Anagen hair loss It can be distinguished from the disease (basically a disease in which atrophied hairs in which the roots of hair in the growth stage are destroyed and a large number of hairs fall out). Of course, even in the above-mentioned telogen effluvium, atrophic hairs may be mixed in with the plucked hairs, and in the above-mentioned anagen alopecia, telogen hairs may also be mixed in with the plucked hairs. However, it is not possible to clearly distinguish between (1) telogen epigenetic alopecia and (2) anagen alopecia simply by the type of hair that is pulled out.
そして、これらの各種脱毛症の原因についての定説は確
立されていない。Furthermore, no established theory has been established regarding the causes of these various types of alopecia.
ところで、ある説によれば、前記休止期性脱毛症の代表
的な例としては、分娩後(出産後)の脱毛症、ビル服用
後脱毛症、男性型脱毛症(若年性脱毛症、壮年性脱毛症
、若はげ)などがあり、その他に炎症性脱毛症、ダイエ
ツト・飢餓性脱毛症、牽引性脱毛症などが例示できる。By the way, according to one theory, typical examples of telogen effluvium include postpartum (after childbirth) alopecia, post-viral alopecia, androgenetic alopecia (juvenile alopecia, middle-age alopecia). Other examples include inflammatory alopecia, diet/starvation alopecia, and traction alopecia.
たとえば、前記分娩後(出産後)の脱毛症およびビル服
用後脱毛症は、女性ホルモンの分泌状態と密接に関係す
るとされており、本来ならば成長期が終わるはずの毛が
女性ホルモン分泌の増加のためにさらに成長期が延長さ
れて休止期毛にならず、正常のホルモン状態になると成
長期の延長していた毛が一斉に脱毛するようになると考
えられている。For example, the aforementioned postpartum (postpartum) alopecia and post-viral alopecia are said to be closely related to the state of female hormone secretion, and hair that should normally have finished its growth phase is due to an increase in female hormone secretion. It is thought that this causes the growth phase to be further extended and the hair does not become telogen, and when normal hormone conditions are reached, the hair that had been in the growth phase begins to fall out all at once.
また、前記男性型脱毛症(若年性脱毛症、壮年性脱毛症
、若はげ)は、その原因として遺伝がその発生の大きな
要因であることは昔からよく知られているところである
。もう一つの原因′は男性ホルモンで、これがとくに毛
母細胞に作用するためとも、一方では男性ホルモンが毛
乳頭に作用するのではないかともいわれている。いずれ
にしても、通常の場合、先に毛周期で述べたように、新
しくできた早期成長期毛は少し成長すると中期成長期毛
となり、少し毛も太く1毛球も大きくなってゆき、脱毛
しないで長くのびた毛は後期成長期毛となって普通の人
の髪となる。しかし、「男性型脱毛症」の初期には後期
成長期毛が沢山抜けるが、抜けた毛孔から再び早期成長
期毛となって少し毛が太くなり始めた頃に男性ホルモン
が作用すると、後期成長期毛という太い毛に育たないま
ま移行期毛を経て休止期毛となって抜けてしまう。つま
り、毛の成長期から休止期への退行速度を速めることと
なり太い毛に育つことなく、細い毛となり毛はうすく見
えるようになるとともに、休止期毛が脱毛すると考えら
れている。Furthermore, it has been well known for a long time that genetics are a major factor in the occurrence of androgenetic alopecia (juvenile alopecia, middle age alopecia, and premature baldness). Another cause is male hormones, which act particularly on hair matrix cells, and it is also said that male hormones act on dermal papillae. In any case, in normal cases, as mentioned earlier regarding the hair cycle, the newly formed early anagen hair grows a little and becomes the middle anagen hair, the hair gets a little thicker and the hair bulb gets bigger, and then hair loss occurs. Hair that grows long without doing so becomes late anagen hair and becomes normal human hair. However, in the early stages of "androgenetic alopecia," a lot of late anagen hair falls out, but when the pores that have fallen out revert to early anagen hair and the hair begins to thicken a little, male hormones act and cause late anagen hair to fall out. Instead of growing into thick hair called stage hair, it passes through transition stage hair and then becomes resting stage hair and falls out. In other words, it is thought that the rate of regression of hair from the growth phase to the resting phase is accelerated, and the hair becomes thinner and thinner without growing thicker, making the hair look thinner and hair in the resting phase being removed.
そこで、従来からこの「男性型脱毛症」に対する養毛剤
・育毛剤にはビタミンEや塩化カロブロニウム、センブ
リエキスなどの血管拡張剤が配合され、毛根周囲と毛乳
頭に分布する毛細血管を拡張して毛球部の栄養の取込み
を良くし、これにより毛の成長を促進させることをはか
ったり、また毛の栄養に必要と考えられるビタミン類と
がアミノ酸などを配合したり、男性ホルモンに拮抗する
女性ホルモンを配合しているものが認められる。Therefore, hair tonics and hair restorers for male pattern baldness have traditionally been formulated with vasodilators such as vitamin E, carobronium chloride, and Oriental chinensis extract. It aims to improve the uptake of nutrients in the bulb and thereby promote hair growth, and it also contains vitamins and amino acids that are considered necessary for hair nutrition, and contains female hormones that counteract male hormones. Those containing the following are recognized.
一方、前記成長期上性脱毛症には、円形脱毛症、薬剤性
脱毛症(抗ガン剤、チアンフェニコールく殺菌剤〉5ホ
ウ酸、タリウムなど)、膠原病に伴う脱毛症等々その病
因は種々様々であり、多岐に亙り一概にその病因を特定
できないとされている。On the other hand, the anagen alopecia include alopecia areata, drug-induced alopecia (anticancer drugs, thiamphenicol, fungicides, 5-boric acid, thallium, etc.), alopecia associated with collagen disease, etc. There are many different types, and it is said that the cause of the disease cannot be definitively identified.
たとえば、前記成長期上性脱毛症の内、円形脱毛症の病
因は「自己免疫説」、「抹消神経異常説」、「ストレス
説・神経ハゲ説」等々と諸説唱えられている。また、医
療用の薬剤を注射したり。For example, among the above-mentioned anagen alopecia, various theories have been proposed regarding the etiology of alopecia areata, including the ``autoimmune theory'', ``peripheral nerve abnormality theory'', and ``stress theory/nerve baldness theory''. Also, injecting medical drugs.
内服したりするうちに脱毛することのある「薬剤性脱毛
症」の代表的なものに「抗ガン剤」による脱毛症が広く
知られているところである。Alopecia caused by anti-cancer drugs is widely known as a representative example of drug-induced alopecia, which can cause hair loss while taking drugs orally.
このように、成長期上性脱毛症の病因は一概に特定でき
ないとしても、結果的には毛の毛母細胞(毛根)が何ら
かの原因で破壊されるために萎縮毛をつ(ることになり
、そのためにかなり激しく成長刈上の脱毛をおこすこと
となるという説が唱えられている。In this way, although the cause of anagen epigenetic alopecia cannot be definitively identified, the result is that the hair matrix cells (hair roots) are destroyed for some reason, resulting in atrophic hair. It has been proposed that this results in hair loss due to rapid growth.
以上のように、脱毛症の病因は種々様々であり一率に論
じることはできないが、脱毛症の共通の原因としては、
毛髪の毛根に異常が生じ毛の本来の寿命を全うすること
なく、(a)毛根が休止期という成長停止または萎縮状
態に陥ったり、 (b)毛根が病的な萎縮状態に陥った
りするためであると考えられている。As mentioned above, the causes of alopecia are various and cannot be discussed uniformly, but the common causes of alopecia are:
An abnormality occurs in the hair root and the hair does not live up to its original lifespan, resulting in (a) the hair root entering a resting phase, where growth stops or it is atrophied, or (b) the hair root falling into a pathological atrophy state. It is believed that
〈発明が解決しようとする問題点〉
このように、脱毛防止の作用機序については、各種脱毛
症の種類により種々様々な病因があり、その病因に応じ
た脱毛防止剤が利用されてきている。脱毛防止効果の作
用機序についてはともかく、植物のハーブエキスまたは
生薬が脱毛防止剤として従来から利用されてきているこ
とは事実である。<Problems to be solved by the invention> As described above, regarding the mechanism of action for preventing hair loss, there are various etiologies depending on the type of alopecia, and anti-hair loss agents have been used depending on the etiology. . Regardless of the mechanism of action of the hair loss prevention effect, it is true that plant herbal extracts or crude drugs have been used as hair loss prevention agents for a long time.
従来の脱毛防止剤として利用されてきたハーブエキスま
たは生薬としては、「西洋菩提樹」、「サルビア」、「
カミツレ」などがある。しかし、これらのハーブエキス
または生薬には、脱毛症の種類または脱毛病因に対する
効果発現に特異性があるという問題点があった。Herbal extracts or herbal medicines that have traditionally been used as anti-hair loss agents include ``Western linden'', ``salvia'', ``
"Chamomile" etc. However, these herbal extracts or herbal medicines have a problem in that they are specific in their effects on the type of alopecia or the cause of alopecia.
そこで、広範囲の各種脱毛症に対して有効で且つ安全性
の高い脱毛防止剤の開発が強く要請されている。Therefore, there is a strong demand for the development of a hair loss prevention agent that is effective against a wide variety of alopecias and is highly safe.
ところで、従来、各種ハーブエキスのうちスギナ抽出物
(水抽出物または/および油抽出物)の作用・効果とし
ては、「抗炎症作用」、「皮膚代謝促進作用」、「血液
循環促進作用」、「抗菌作用」、「防腐作用」、「結合
組織の抵抗力の増大作用」および「細胞賦活作用Jが公
知である。上記作用・効果に基づき、従来、スギナは歴
史的には民間薬や美容効果薬(化粧品)として用いられ
、たとえばその利尿作用による前側として、外用につい
て止血、化膿性潰瘍・陳旧創面・皮疹に洗浄剤として、
また慢性湿疹・神経皮膚炎・局所の血行障害等に対する
浴剤として、さらには全身の代謝促進作用による体臭除
去剤などに利用されてきた。By the way, conventionally, among various herbal extracts, the actions and effects of horsetail extract (water extract and/or oil extract) include "anti-inflammatory action,""skin metabolism promotion action,""blood circulation promotion action," It is known for its "antibacterial action,""preservativeaction,""increasing connective tissue resistance," and "cell activating action."Based on the above actions and effects, horsetail has historically been used in folk medicine and cosmetics. It is used as an effective medicine (cosmetics), for example, as a diuretic agent, for external use to stop bleeding, and as a cleansing agent for purulent ulcers, old wounds, and skin eruptions.
It has also been used as a bath additive for chronic eczema, neurodermatitis, local blood circulation disorders, etc., and as a body odor remover due to its ability to promote systemic metabolism.
しかし、スギナ抽出物が有する前記各種作用・効果のう
ち「細胞賦活作用」は養毛効果との関係を否定できない
までも脱毛防止効果とは全く無関係のものである。また
、従来前記スギナ抽出物には、前記西洋菩提樹、サルビ
ア、カミツレなどのような「脱毛防止作用」があること
は全熟知られていない。However, among the various actions and effects that horsetail extract has, the "cell activating action" is completely unrelated to the hair loss prevention effect, although its relationship with the hair-nourishing effect cannot be denied. Furthermore, it is not well known that the horsetail extract has a "hair loss prevention effect" like that of the linden tree, salvia, chamomile, and the like.
前記問題点を解決すべく検索・研究の結果、スギナ抽出
物(スギナ水抽出物、スギナ溶剤抽出物および/または
スギナ油抽出物)が広範囲の脱毛症(つまり広範囲の病
因に起因して生ずる脱毛症)に有効に適用でき、且つ極
めて安定性および安全性が高という事実を発見したこと
により、この発明は完成された。As a result of searches and research to solve the above problems, it was found that horsetail extract (horsetail water extract, horsetail solvent extract and/or horsetail oil extract) can be used to treat a wide range of alopecias (that is, hair loss caused by a wide range of etiologies). The present invention was completed based on the discovery that it can be effectively applied to patients with cancer and has extremely high stability and safety.
この発明は、上記各種病因により住する広範囲の各種脱
毛症に対して顕著な効果を奏する脱毛防止剤であって、
しかも安全かつ安定な脱毛防止剤を提供することを目的
とする。The present invention is a hair loss prevention agent that has remarkable effects on a wide variety of alopecias caused by the various etiologies mentioned above,
Moreover, the object is to provide a safe and stable anti-hair loss agent.
く問題点を解決するための手段〉
この発明は、上記発明の目的を達成するために、脱毛防
止のための有効成分として、スギナ抽出物を含むことを
特徴とする脱毛防止剤を構成することとした。Means for Solving the Problems> In order to achieve the above object, the present invention provides a hair loss prevention agent characterized by containing horsetail extract as an active ingredient for hair loss prevention. And so.
この発明にかかる脱毛防止剤は、前記〈発明が解決しよ
うとする問題点〉の項で略述したように、各種病因によ
り生ずる広範囲の各種脱毛症に対して顕著な効果を奏す
る脱毛防止剤である。すなわち、この発明にかかる脱毛
防止剤が適用できる各種脱毛症としては次のものが例示
できる。The hair loss prevention agent according to the present invention is a hair loss prevention agent that exhibits remarkable effects on a wide range of various types of alopecia caused by various etiologies, as briefly explained in the section of <Problems to be solved by the invention>. be. That is, the following are examples of various alopecias to which the anti-hair loss agent according to the present invention can be applied.
なお、ここでの前記各種脱毛症の例示は、ある説による
脱毛症の分類に基づいて記載することとした。Note that the various types of alopecia mentioned above are described based on the classification of alopecia according to a certain theory.
A)休止期上性脱毛症の例。A) Example of telogen epigenetic alopecia.
(a)男性型脱毛症
(b)炎症性脱毛症
・フケ症による脱毛症
・脂漏性脱毛症
・接触性皮膚炎による脱毛症
(C)分娩後(出産後)脱毛症
(d)ピル服用後脱毛症
(e)ダイエツト・飢餓性脱毛症
(f)牽引性脱毛症
(6)圧迫性脱毛症
(ハ)甲状腺機能低下症
(i)甲状腺機能先進症
0)下垂体機能低下症
(ロ)副甲状腺機能低下症
(1)薬物脱毛症
・ビタミンA過剰症
・抗凝固剤−ヘパリン、ヘパリノイド等・抗精神剤−ト
リバラノール等
・抗甲状腺剤−チオウラシル等
・その他
B)成長刈上性脱毛症
(a)円形脱毛症
(b)薬荊脱毛症
・抗ガン剤
・チアンフェニコール(111剤)
・ホウ酸、タリウムなど
・その他
(C)li性指端皮膚炎による脱毛症
(d)膠原病(SLE、DLE、開側状強皮症など)に
伴う脱毛症
(e)ムチン沈着性脱毛症
(f)@痕性脱毛症
(g)!J[部白廖−系状菌感染症による脱毛症等々、
この発明にかかる脱毛防止剤は、上記各種脱毛症に対し
て広範囲に適用できる。ただし、前記(A)休止期性脱
毛症のうち(ロ)炎症性脱毛症に対して、この発明にか
かるスギナ抽出物が特に優れた効果を奏するのは、この
発明にががるスギナ抽出物の「脱毛防止効果」に加えて
、スギナ抽出物の「抗炎症作用」および「抗菌作用j等
との相乗作用に基づきより一層顕著な効果を奏するもの
と推測される。(a) Androgenetic alopecia (b) Alopecia due to inflammatory alopecia/dandruff/seborrheic alopecia/contact dermatitis (C) Postpartum (after childbirth) alopecia (d) Pill use Post-alopecia (e) Diet/starvation alopecia (f) Traction alopecia (6) Compression alopecia (c) Hypothyroidism (i) Advanced thyroid function 0) Hypopituitarism (b) Hypoparathyroidism (1) Drug alopecia, hypervitaminosis A, anticoagulants - heparin, heparinoids, etc., antipsychotics - tribalanol, etc., antithyroid drugs - thiouracil, etc., etc. B) Growth alopecia ( a) Alopecia areata (b) Alopecia areata, anticancer drugs, thiamphenicol (111 drugs), boric acid, thallium, etc., others (C) Alopecia due to digital dermatitis (d) Collagen disease ( Alopecia associated with SLE, DLE, open scleroderma lateralis, etc.) (e) Mucin deposition alopecia (f) @ Scarring alopecia (g)! J [Bu Bai Liao - Alopecia due to fungal infections, etc.
The anti-hair loss agent according to the present invention can be widely applied to the various alopecias mentioned above. However, among (A) telogen alopecia, the horsetail extract according to the present invention has a particularly excellent effect on (b) inflammatory alopecia. In addition to the ``hair loss prevention effect'', it is presumed that the effect is even more pronounced due to the synergistic effect with the ``anti-inflammatory effect'' and ``antibacterial effect'' of the horsetail extract.
この発明にかかる脱毛防止剤、すなわちスギナ抽出物は
、トクサ科の薬用植物であるスギナ(EquiseLU
m arvense L、 )の葉、茎、栄養茎
胞子茎および全軍から選ばれた1または2以上を抽出原
料とし、この原料から抽出用溶剤として水および有機溶
剤から選択された単独液または2以上の溶剤の混合液を
用いて抽出することにより得られる。The anti-hair loss agent of this invention, that is, horsetail extract, is derived from horsetail (EquiseLU), which is a medicinal plant of the horsetail family.
The leaves, stems, vegetative shoots, and one or more selected from the entire army are used as extraction raw materials, and from this raw material, a single solution or two or more selected from water and organic solvents are used as extraction solvents. It is obtained by extraction using a mixture of solvents.
原料として用いられる植物のスギナは、その収穫季節を
特に限定されないけれども、夏期に収穫した活力旺盛な
ものが特に好ましい、また、スギナの全軍が利用できる
ことは前述の七おりであるが、なかでも栄養茎が特に好
ましい、そして、スギナ抽出物の調製に際しては、原料
保存性の観点より、原料のスギナの植物体を乾燥した後
に前記水または/および有機溶剤により抽出するのが好
ましい。The harvest season of the horsetail plant used as a raw material is not particularly limited, but it is particularly preferable to have vigorous horsetail harvested in the summer. A vegetative stem is particularly preferred, and when preparing a horsetail extract, from the viewpoint of preserving the raw material, it is preferable to dry the raw material horsetail plant and then extract with the water or/and organic solvent.
次に、原料のスギナの植物体からスギナ抽出物を調製す
るのに用いられる溶剤について述べる。Next, the solvent used to prepare the horsetail extract from the raw horsetail plant will be described.
水は精製水または蒸留水が好ましい。有機溶剤は、炭素
数2〜5の1価アルコールまたは多価アルコールが利用
することができ、特に前記アルコールの例示としてはエ
タノール、プロピレングリコール、l、3−ブチレング
リコール、グリセリンなどが好適である。さらには、抽
出用溶剤として、植物油等の各種グリセリドが利用でき
、たとえばヒマワリ油などが好適である。The water is preferably purified water or distilled water. As the organic solvent, a monohydric alcohol or a polyhydric alcohol having 2 to 5 carbon atoms can be used, and particularly preferred examples of the alcohol include ethanol, propylene glycol, 1,3-butylene glycol, and glycerin. Furthermore, various glycerides such as vegetable oils can be used as extraction solvents, with sunflower oil and the like being preferred.
原料のスギナ(Equisetum arvense
L、 )からこの発明にかかるスギナ抽出物の調製
方法は、いずれも公知の方法による。Raw material horsetail (Equisetum arvense)
The method for preparing the horsetail extract according to the present invention from L, ) is performed by any known method.
たとえば、水により抽出する場合の例は、細粉した乾燥
スギナ(Equjsetum arvense L
、 )の1重量部に対して約5〜200重量部の精製水
を加え室温侵出(侵出条件:約10℃〜35℃、約5日
〜10日間、好ましくは6日〜8日間)して侵出液を、
若しくは加熱(加熱条件;約80〜100°C9約30
分〜3時間)して煎出液を得る。このようにして得られ
た前記侵出液および煎出液は、もとよりこの発明にかか
るスギナ抽出物にほかならない。For example, in the case of extraction with water, finely powdered dried horsetail (Equjsetum arvense L.
About 5 to 200 parts by weight of purified water is added to 1 part by weight of , ) and leached at room temperature (leaching conditions: about 10°C to 35°C, about 5 to 10 days, preferably 6 to 8 days). and exudate,
or heating (heating conditions: approx. 80-100°C9 approx. 30
minutes to 3 hours) to obtain a decoction. The exudate and decoction thus obtained are of course the horsetail extract according to the present invention.
したがって、前記侵出液および煎出液は、原液そのまま
てこの発明にかかるスギナ抽出物として使用することが
できる。また、前記侵出液および煎出液は、必要に応じ
て適当な濃度に濃縮し、この発明にかかるスギナ抽出物
として使用することもできる。さらには、前記侵出液お
よび煎出液の抽出用溶剤(この例の場合は水)を留去、
蒸発または蒸散させてこの発明にかかる乾燥スギナ抽出
物として使用することができるのはいうまでもない。た
とえば、−船釣なスギナ抽出物の調製例としては、乾燥
スギナ10kgから約101〜502程度の濃度のもの
(原液または濃縮液)を得る。このスギナ抽出物の性状
は、−船釣にいって外観が淡黄緑色ないし茶色の透明な
液体で特異臭を有する。Therefore, the exudate and decoction can be used in their original form as the horsetail extract according to the present invention. Furthermore, the exudate and decoction can be concentrated to an appropriate concentration as necessary and used as the horsetail extract according to the present invention. Furthermore, the extraction solvent (water in this example) of the exudate and decoction is distilled off,
It goes without saying that the dried horsetail extract according to the present invention can be used after evaporation or transpiration. For example, as an example of preparing a horsetail extract, one having a concentration of about 101 to 502 (undiluted solution or concentrated solution) is obtained from 10 kg of dried horsetail. The properties of this horsetail extract are as follows: - It is a clear liquid with a pale yellowish green to brown appearance and a distinctive odor when used for boat fishing.
このようにして得た前記スギナ抽出物(原液。The horsetail extract thus obtained (undiluted solution).
濃縮液または乾燥物)は、使用に際して原液、I!縮液
または乾燥物それぞれそのままを後述の処方例に従って
使用するか、または適当な溶剤、たとえば水、エタノー
ル、希エタノール、プロピレングリコール、1,3−ブ
チレングリコールまたはグリセリン等の溶剤の単独液ま
たは混合液、または/および各種化粧料基材に溶解また
は混和希釈して使用する。Concentrated solution or dried product) is used as a undiluted solution, I! Either the condensed liquid or dried product can be used as it is according to the formulation examples described below, or a single solution or a mixture of solvents such as water, ethanol, diluted ethanol, propylene glycol, 1,3-butylene glycol, or glycerin can be used. , or/and used by dissolving or diluting it in various cosmetic base materials.
また、スギナ抽出!(乾燥粉末抽出@ff)の他の調製
例としては、原料のスギナ(Equisetu■arv
ense L、 )を水で、60℃以下で1〜2週
間侵出しエキスを抽出する。この抽出物は減圧下(約2
QssiHg〜30■鴎Hg)で60°Cを越えないよ
うにして、蜂蜜様の粘稠な状態になるまで濃縮する。次
いで、溶解性を増すために、水に溶かし濾過・精製する
。濾液は減圧下で60℃以下の温度で濃縮・乾燥して得
られた固型物は粉砕し篩にかけて粉体とする (茶色の
粉末)、このようにして得られるスギナ抽出物(水抽出
物の乾燥体)は原料スギナの約10〜13%前後であり
、このスギナ抽出物(水抽出物の乾燥体)は適当な溶剤
、たとえば水、エタノール、希エタノール、プロピレン
グリコール。Also, horsetail extract! As another preparation example of (dry powder extraction @ff), the raw material horsetail
ense L, ) with water at 60° C. or lower for 1 to 2 weeks to extract the extract. This extract was extracted under reduced pressure (approximately 2
Concentrate at a temperature of QssiHg~30■KuHg) without exceeding 60°C until it becomes a honey-like viscous state. Next, to increase solubility, it is dissolved in water and filtered and purified. The filtrate is concentrated and dried under reduced pressure at a temperature below 60°C. The solid substance obtained is crushed and sieved to form a powder (brown powder). The horsetail extract (dried form of water extract) is about 10 to 13% of the raw horsetail horsetail, and the horsetail extract (dried form of water extract) is prepared using a suitable solvent such as water, ethanol, diluted ethanol, propylene glycol.
1.3−ブチレングリコールまたはグリセリン等の溶剤
または/および化粧料基材に溶解または混和希釈して使
用する。1. It is used by dissolving or diluting it in a solvent such as 3-butylene glycol or glycerin and/or a cosmetic base material.
他の例として、有機溶剤を抽出用溶剤として用いてスギ
ナ抽出物を調製する場合として、たとえばエタノールを
例にすると、原料の乾燥スギナ(Equisetua
arvense L、 )の全草1重量部に対し
て5%〜99.9%のエタノール約5〜200重量部を
加え、約1〜3週間冷浸したのち、濾過する。この濾液
を水浴上で減圧濃縮し、濃縮液を約10分の1 (第1
濃縮液)にする。この第1濃縮液1容量部に対して精製
水約2容量部を加え、生じる沈澱を濾過して除き、その
後さらに濾液を水浴上で減圧濃縮し、液量を約半量とし
、濃縮液にエタノールおよび精製水を適量加えて全量を
前記第1濃縮液量の約2〜5倍量でアルコール濃度50
%に調整する。これを冷所に約20〜30日間放置し。As another example, when an organic solvent is used as an extraction solvent to prepare a horsetail extract, taking ethanol as an example, dry horsetail (Equisetua) as a raw material is used.
Approximately 5 to 200 parts by weight of 5% to 99.9% ethanol is added to 1 part by weight of the whole plant of P. arvense L.), and the mixture is cooled for about 1 to 3 weeks and then filtered. This filtrate was concentrated under reduced pressure on a water bath, and about 1/10 of the concentrated liquid (1st
Concentrate). Approximately 2 parts by volume of purified water is added to 1 part by volume of this first concentrate, the resulting precipitate is filtered off, the filtrate is further concentrated under reduced pressure on a water bath to reduce the liquid volume to about half, and ethanol is added to the concentrate. Then, add an appropriate amount of purified water and make the total volume about 2 to 5 times the volume of the first concentrated liquid to an alcohol concentration of 50.
Adjust to %. Leave this in a cool place for about 20 to 30 days.
必要ならば濾過し、最終スギナ抽出物として前記第1濃
縮液の約2〜8容量部を得る。このようにして得た最終
スギナ抽出物は、前記スギナ水抽出物の場合と同様、使
用に際して前記最終スギナ抽出物の原液そのままを後述
の処方(用法)に従って使用するか、または適当な溶剤
たとえば水、エタノール、希エタノール、プロピレング
リコール、l、3−ブチレングリコールまたはグリセリ
ンなどその他の有機溶剤または/および化粧料基材に溶
解または混和希釈して使用する。Filter if necessary to obtain about 2 to 8 parts by volume of the first concentrate as the final horsetail extract. When using the final horsetail extract thus obtained, as in the case of the water extract of horsetail, the final solution of the horsetail extract can be used as it is according to the recipe (method of use) described below, or it can be used in a suitable solvent such as water. , ethanol, diluted ethanol, propylene glycol, 1,3-butylene glycol, or other organic solvents such as glycerin or/and cosmetic base materials.
さらにまた、この発明にかかるスギナ抽出物は、スギナ
エキスまたは油溶性スギナエキスとして、従来の公知作
用・効果つまり前述の「抗炎症作用」、「皮膚代謝促進
作用」、「血液循環促進作用」、「抗菌作用」、「防腐
作用J、r結合組織の抵抗力の増大」および「細胞賦活
作用」の従来の公知作用・効果を奏する使用前例に基づ
き化粧品種別許可基準■などに掲載されている。また、
この発明にかかるスギナ抽出物は、化粧品等の原料メー
カー各社からいわゆる市販の各種スギナエキス(Hor
setatl Extract )および各種油溶
性スギナエキス(04l−Soluble Hors
etailExtract ) (液状および乾燥粉
末状を問わず〕等々として製造販売されている。前記化
粧品種別許可基準■等の掲載にかかるスギナエキスおよ
び油溶性スギナエキス並びに前記市販にかかる各種スギ
ナエキスは、この発明にかかる脱毛防止剤さして利用で
きるのは勿論である。Furthermore, the horsetail extract according to the present invention, as a horsetail extract or an oil-soluble horsetail extract, has conventionally known effects and effects, that is, the above-mentioned "anti-inflammatory action,""skin metabolism promoting action,""blood circulation promoting action," It is listed in the Cosmetic Type Permission Criteria (■) based on the usage examples that have the known actions and effects of "antibacterial action,""preservativeaction,""increase of connective tissue resistance," and "cell activating action." Also,
The horsetail extract according to the present invention is a variety of commercially available horsetail extracts (Hor
setatl Extract) and various oil-soluble horsetail extracts (04l-Soluble Hors
etailExtract) (regardless of liquid or dry powder form), etc.The horsetail extract and oil-soluble horsetail extract listed in the above-mentioned Cosmetic Type Permission Criteria (■), as well as the various commercially available horsetail extracts, are subject to the present invention. Of course, it can also be used as a hair loss prevention agent.
つぎに、この発明にかかる脱毛防止剤の用法について述
べる。スギナ抽出物(前記調製方法により調製された各
種スギナ水抽出物、各種スギナ溶剤抽出物およびスギナ
油抽出物、並びに前記市販の液状または乾燥粉末状の各
種スギナ抽出物および市販の液状または乾燥粉末状の各
種油溶性スギナエキスをも含む、以下これら全てを含め
たものを「スギナ抽出物」という、以下同じ、)は、原
液または適当な溶剤等(水、有機溶剤または/および各
種化粧料基材を含む、以下これら全てを含めたものを[
溶剤等Jという、以下おなし、)を用いて適当な濃度に
希釈または混和して病患部に塗布または塗擦する。Next, the usage of the antihair loss agent according to the present invention will be described. Horsetail extracts (various horsetail water extracts, various horsetail solvent extracts and horsetail oil extracts prepared by the above-mentioned preparation methods, various horsetail extracts in the form of commercially available liquids or dry powders, and various horsetails extracts in the form of commercially available liquids or dry powders) (including various oil-soluble horsetail extracts, hereinafter referred to as "horsetail extracts"; hereinafter the same shall apply) may be used as a undiluted solution or in a suitable solvent (water, organic solvent or/and various cosmetic base materials). , including all of these below [
It is diluted or mixed with a solvent (hereinafter referred to as "A") to an appropriate concentration and applied or rubbed onto the affected area.
この発明にかかる脱毛防止剤、つまりスギナ抽出物の適
切な原液の濃度および各種使用液の希釈濃度は、原則的
には有効量で皮膚炎等の副作用が生じない程度であれば
良く、画一的にこの発明にかかる脱毛防止剤の使用濃度
を論することは困難である。なぜなら、使用者の個体差
(自己免疫性の有無・男女の別・体調などなど)、脱毛
症の病因とその脱毛症状の進行程度、脱毛にかかる毛の
毛周期における分布・比率などにより、患部に塗布・塗
擦されるスギナ抽出物の濃度、−日の塗布・塗擦回数、
塗布・塗擦期間などが決せられるからである。具体的な
実施例に基づき経験則的にこの発明にかかる脱毛防止剤
の用法を各自の症例等に適合する条件を決定することが
肝要である。さらにまた、この発明にかかるスギナ抽出
物の各種製品中への配合量は、当該製品の品種によって
適宜変化されるべきであることはいうまでもない。The hair loss prevention agent according to the present invention, that is, the appropriate concentration of the stock solution of horsetail extract and the dilution concentration of various solutions for use, should be in principle an effective amount that does not cause side effects such as dermatitis, and should not be uniform. Therefore, it is difficult to discuss the concentration of the antihair loss agent according to the present invention. This is because the affected area varies depending on the individual differences of the user (presence of autoimmunity, gender, physical condition, etc.), the etiology of alopecia and the degree of progression of the hair loss symptoms, the distribution and ratio of hair related to hair loss in the hair cycle, etc. Concentration of horsetail extract applied/rubbed, number of application/rubbing per -day,
This is because the application/scrubbing period and the like are determined. It is important to determine the usage conditions of the antihair loss agent according to the present invention based on specific examples and empirically to suit each case. Furthermore, it goes without saying that the amount of the horsetail extract according to the present invention incorporated into various products should be changed as appropriate depending on the variety of the product.
各種製品中へのスギナ抽出物の配合量の一般的な目安量
として、スギナ抽出物の実用的な配合濃度範囲はスギナ
抽出物(粗抽出物または/および精製抽出物を含む)の
乾燥重量の配合量として約0.1重量%ないし40重量
%において実用的配合に使用でき、なかでも0.5重量
%ないし20重量%が好ましく、さらには1.0重量%
ないし10重量%が実用的配合量として最適である。As a general guideline for the amount of horsetail extract incorporated into various products, the practical concentration range of horsetail extract is based on the dry weight of horsetail extract (including crude extract and/or purified extract). It can be used in practical formulations in a blending amount of about 0.1% to 40% by weight, preferably 0.5% to 20% by weight, more preferably 1.0% by weight.
The optimum practical amount is between 10% and 10% by weight.
そして、この発明にかかる脱毛防止剤は、少なくとも前
記スギナ抽出物が構成成分として含まれている限り有効
であり、他の公知の脱毛防止剤とスギナ抽出物とが併用
されていても良いのはいうまでもない。The anti-hair loss agent according to the present invention is effective as long as it contains at least the horsetail extract as a constituent component, and horsetail extract may be used in combination with other known anti-hair loss agents. Needless to say.
この発明にかかる脱毛防止剤は、各種香粧品に配合する
ことにより、ヘアケア製品(特に頭髪用化粧品など)全
般および医薬部外品等を提供することができる。前記各
種ヘアケア製品(頭髪用化粧品)の例としては、ヘアト
ニック、ヘアエツセンス、ヘアシャンプー、ヘアリンス
、ヘアトリートメント(ヘアコンディショナー)、ヘア
クリーム、整髪料、などその他の頭髪用化粧品が例示で
きる。一方、医薬部外品の例として、養毛・育毛を目的
とした薬用ローション、薬用ヘアトニックなどのばかパ
ーマネント・ウェーブ液、ヘアダイ(染毛剤などその他
)、ヘアクリーム剤などその他の頭髪用化粧品が例示で
きる。そして、前記各種香粧品(化粧品または/および
医薬部外品を含む)の通用形態としては、液状、クリー
ム状、ゼリー状、粉末状、固型状、乳液状、ゾル状また
は/およびゲル状、スプレー状(エアゾル状)等々その
通用形態に制限はなく、はとんど全ての形態にて使用で
きる。The anti-hair loss agent according to the present invention can be incorporated into various cosmetics to provide general hair care products (particularly hair cosmetics, etc.), quasi-drugs, and the like. Examples of the various hair care products (hair cosmetics) include hair tonics, hair essences, hair shampoos, hair rinses, hair treatments (hair conditioners), hair creams, hair styling products, and other hair cosmetics. On the other hand, examples of quasi-drugs include medicated lotions for hair growth, medicated hair tonics and other permanent wave liquids, hair dyes (hair dyes and others), hair creams, and other hair cosmetics. can be exemplified. The common forms of the various cosmetics (including cosmetics and/or quasi-drugs) include liquid, cream, jelly, powder, solid, emulsion, sol and/or gel, There is no limit to its common form, such as spray form (aerosol form), and it can be used in almost all forms.
〈作用〉
この発明は、スギナ抽出物が有する毛根に栄養を与え、
特に頭髪などの体毛の成長を促進して成長期から休止期
に入る退行速度を遅延し又は休止期突入を防止すること
による脱毛防止作用および毛根の萎縮現象を防止するこ
とによる脱毛防止作用に基づき、極めて優れた休止刈上
性脱毛の防止および成長期上性脱毛の防止を図ることが
できるしかも、この発明にかかる脱毛防止剤は、脱毛症
状のないヒトの正常な毛髪には全く悪影響を与えること
がなくその正常な状態を維持するという優れた作用効果
を有する。<Action> This invention provides nutrients to the hair roots of horsetail extract,
In particular, based on the hair loss prevention effect by promoting the growth of body hair such as scalp hair, delaying the rate of degeneration from the growth phase to the telogen phase, or preventing the transition to the telogen phase, and the hair loss prevention effect by preventing hair root atrophy. Although it is possible to achieve extremely excellent prevention of telogen hair loss and prevention of anagen hair loss, the hair loss prevention agent according to the present invention has no adverse effect on normal hair of humans without symptoms of hair loss. It has an excellent effect of maintaining its normal state without any problems.
〈実施例〉 (1)スギナ抽出物の調製例。<Example> (1) Example of preparation of horsetail extract.
乾燥スギナ100gに対して50%エタノール2.00
0gを混合し、室温く約20°C)で約7日間抽出後、
濾過してスギナ抽出物的1 、500gを得る。50% ethanol 2.00% for 100g of dried horsetail
After mixing 0g and extracting at room temperature (about 20°C) for about 7 days,
Filter to obtain 500 g of horsetail extract.
この明細書において、実施例として例示された香粧品等
の各種製品中に配合されたこの発明にかかるスギナ抽出
物の配合量(重量%<wt%〉)は、乾燥スギナ抽出物
としての配合量(wt%)を示すものである。In this specification, the amount (weight%<wt%>) of the horsetail extract according to the present invention blended into various products such as cosmetics illustrated as examples is the amount of the horsetail extract as a dried horsetail extract. (wt%).
また、スギナ油抽出物を得る場合には、前記調製例にお
いて、50%エタノールに替えてヒマワリ油を用いて抽
出する。このスギナ油抽出物は、たとえばポマードなど
のような水の入っていない製品に配合する場合に使用す
ると好適である。Furthermore, when obtaining a horsetail oil extract, extraction is performed using sunflower oil instead of 50% ethanol in the preparation example. This horsetail oil extract is suitable for use when incorporated into water-free products such as pomades.
(2)この発明にかかる脱毛防止剤の各症例に対する効
果試験実施例。(2) Effect test examples for each case of the antihair loss agent according to the present invention.
この効果試験実施例は、各脱毛症状を訴えている被験者
の抜は毛数を経時的に計測する公知の方法により試験し
た。This effectiveness test example was conducted using a known method of measuring the number of hairs pulled out over time by test subjects complaining of various hair loss symptoms.
(a)試験材料
本効果試験実施例において使用した製品は、この発明に
かかる脱毛防止剤を配合した次に示す処方組成のヘアト
ニックを各被験者に使用させた。(a) Test Materials The product used in this effect test example was a hair tonic containing the hair loss preventing agent according to the present invention and having the following formulation composition, which was used by each subject.
☆試験使用したヘアトニックの処方組成〔配合量はいず
れも重量%(wt%〕を示す〕(iit%)
・エタノール−・−・−一−−−−−〜−−−・−−一
−−−−・−一一−−−・・−・・50.0・スギナ抽
出物・・・・−・・−・−・・−・=・・・−・・・−
・−・・・・・ 0.6・グリセリンー−一−−−−・
・−・−・−・−・・−・−・−・−・・・・−1,0
・t−メン)−ル・−・・・・・・−・・・・・・・・
・・・・・・・・・・・・−一−−・ 0.1ポリオキ
シエチレン
モノラウレート・・・・−・・・−・−・−・−・・−
・〜 0.5・香料・色素・・−・・・・・・・・−・
−・・−一−−−−・・・・−・・−・・・−・−適量
・精製水−・−・・−一−−−−−−−−−−−−・−
−−−−一−〜・−−−−−−一全量100■)投与方
法および投与期間。☆Formulation composition of the hair tonic used in the test [All blending amounts are in weight% (wt%)] (IIT%) ・Ethanol - - - - - - - - - ~ - - - - - - −−−・−11−−−・・−・・50.0・Equisetum extract・・・・−・・−・−・・−・=・・・−・・−
・-・・・・・・ 0.6・Glycerin-----・
・−・−・−・−・・−・−・−・−・・・・・−1,0
・T-men)-ru・・・・・・・・・・・・・・・・・・・・
......
・~ 0.5・Fragrance・Pigment・・・・・・・・・・・・・・−・
−・・−1−−−−・・・・−・・−・・・−・−Appropriate amount of purified water−・−・・−1−−−−−−−−−−−−・−
--------------------Total amount 100 ■) Administration method and administration period.
前記試験ヘアトニックを1日2回(朝、夜)・適量(1
回:1.5〜2m)を脱毛部位に塗擦させた。投与期間
は、全期間で12週間とし、前記試験ヘアトニックの交
付は原則として3週間率位;10バイアル(1バイアル
7d人)とした。なお、この効果試験実施期間中におい
て、被験者に対して脱毛症の治療を目的としたいかなる
薬剤の使用も禁止した。Apply the above test hair tonic twice a day (morning and evening) in an appropriate amount (1
1.5 to 2 m) was rubbed onto the hair removal site. The administration period was 12 weeks in total, and the test hair tonic was distributed for 3 weeks in principle; 10 vials (1 vial for 7 people). Furthermore, during the implementation period of this efficacy test, subjects were prohibited from using any drug for the purpose of treating alopecia.
(C)観察項目および試験方法
☆観察口および測定項目
観察口は、試験開始前、8週間後、12週間後の被験者
の洗髪時の抜は毛の数を測定した。(C) Observation items and test method ☆Observation port and measurement items At the observation port, the number of hairs pulled out when the test subject was washing their hair was measured before the start of the test, 8 weeks later, and 12 weeks later.
☆洗髪時の抜は毛の数の試験方法
試験開始前、8週間後、12週間後の各時期の洗髪時に
抜ける毛を回収し、充分陰干しした後、抜は毛の本数を
測定した。☆ Test method for determining the number of hairs removed during hair washing Before the start of the test, 8 weeks later, and 12 weeks later, the hairs that were removed during hair washing were collected, dried thoroughly in the shade, and the number of removed hairs was measured.
試験方法は、前記各時期において、1日間隔で洗髪を実
施した。たとえば、試験開始前の抜は毛の測定には、1
週間のうち奇数日(第1.3,5.7日)を洗髪日とし
、その肉筆3.5.7日の洗髪時を抜は毛の回収日とし
3回の洗髪時の抜は毛の合計数を計測した。また8週間
後および12週間後の抜は毛数については、各翌週つま
り第9週日および第13週日を抜は毛測定週間とし、当
該第9週日および第13週日の第1゜3.5.7日を洗
髪日とし、その内当該週の第3.5.7日を抜は毛回収
日としてこの3回の洗髪時の抜は毛の合計を測定した洗
髪時には、所定のプラスチックス製ザル(内径的35c
m)にメツシュの非常に細かい不織布を2枚かぶせ、そ
の上で洗髪を行った。この試験期間中に使用するヘアジ
ャンプ、ヘアリンスは試験開始前に被験者の各自が使用
していた商品を変えずにそのまま使用させた。The test method was to wash the hair at one-day intervals in each of the above periods. For example, to measure plucked hair before starting the test, 1
The odd numbered days of the week (1st, 3rd, 5th, 7th) are designated as hair washing days, and the hair washing on the 3rd, 5th, and 7th day of the week is designated as the hair collection day. The total number was counted. Regarding the number of hairs removed after 8 weeks and 12 weeks, each following week, that is, the 9th week day and the 13th week day, is the hair removal measurement week, and the 1st 3.5. The 7th day is designated as a hair washing day, and the 3rd, 5th, and 7th days of the week are designated as hair removal and hair collection days. (inner diameter 35c
(m) was covered with two very fine mesh nonwoven fabrics, and the hair was washed on top of that. The hair jump and hair rinse used during this test period were the same as the products each subject had been using before the start of the test.
試験期間中、被験者にはヘアトニックの使用状況、洗髪
の有無、Wk髪日、副作用の有無などについて日記を記
録させた。そして、「散髪による切断上」と「抜は毛」
との区別が困難であるため、「抜は毛」測定の日より1
週間前以内の散髪を禁止した。During the test period, the subjects kept a diary to record the usage status of the hair tonic, whether or not they washed their hair, the number of days they wore their hair, and the presence or absence of any side effects. And "cutting due to haircut" and "hair removal"
Since it is difficult to distinguish between
Haircuts within the previous week were prohibited.
観察口および被験者が記録した日記により、副作用の調
査をした。副作用が発生した場合、その程度を軽度・中
等度・高度の3段階に区別し、記録した。高度とは、皮
膚炎その他の症状により試験が続行できない程度のもの
とした。なお、今回おこなった被験者23名については
、−人も中等度以上の副作用を訴えるものがいなかった
。この結果より、この発明にかかる脱毛防止剤(スギナ
抽出物)は、極めて安全性が高いことを示唆している。Side effects were investigated using observation ports and diaries recorded by the subjects. When side effects occurred, the severity was categorized into three levels: mild, moderate, and severe, and recorded. Severe condition was defined as a degree to which the test could not be continued due to dermatitis or other symptoms. Of the 23 subjects tested this time, none complained of moderate or higher side effects. This result suggests that the antihair loss agent (horsetail extract) according to the present invention is extremely safe.
さらには、脱毛症を呈していない正常なヒトに対しては
同等悪影響がなかったことより、この発明にかかる脱毛
防止剤は極めて安全性が高いことを示唆している。Furthermore, since there was no similar adverse effect on normal humans who do not exhibit alopecia, it is suggested that the anti-hair loss agent according to the present invention is extremely safe.
☆この効果試験実施例結果、つまり「洗髪時の抜は毛数
の結果例」を第1表に示す。☆The results of this effect test, ie, "Example results of the number of hairs removed during hair washing" are shown in Table 1.
第1表の結果より、■この発明にかかる脱毛防止剤は、
広範囲の各種脱毛症に対して極めて有効であることが示
唆されている。■各種脱毛症に対するこの発明にかかる
脱毛防止剤は、使用期間8週間後においては危険率5%
で有意差が認められ、使用期間12週間後においては危
険率1%で有意差が認められる。このことよりこの発明
にかかる脱毛防止剤は、短期間の使用で極めて優れた脱
毛防止効果を奏することを示唆している。From the results in Table 1, ■ the hair loss prevention agent according to the present invention is
It has been suggested that it is extremely effective against a wide variety of alopecias. ■The hair loss prevention agent of this invention for various types of alopecia has a risk rate of 5% after 8 weeks of use.
A significant difference was observed, and after 12 weeks of use, a significant difference was observed with a risk rate of 1%. This suggests that the hair loss preventing agent according to the present invention exhibits an extremely excellent hair loss prevention effect even when used for a short period of time.
c本頁以下余白〕
電1害:壓響時の抜は毛の数1嘘0
【3回の合計ヲ記載/ t)Mi:: ” 1405/
軸AOD(3)その他の各種頭髪用化粧品の処方例を次
に例示する。なお、この処方例に限定されないことはい
うまでもない。 (実施例における配合比率はいずれも
重量%(wt%)を示す
(A)ヘアエツセンス
・エタノール
・ヒマシ油
・スギナ抽出物
・香料1色素
・精製水
(wt%)
65.0%
5.0
1.0
適量
全量100
(B)
ヘアシャンプー
アルキルエーテル
硫酸ナトリウム −・−・−一−−−−−−−−−−・
−・・エタノール
ラウリン酸ジェタノールアミド・−・−プロピレングリ
コール・−・−・・・・・・・・・−・・而・スギナ抽
出物
防腐剤1色素、香料−−−−−−−・−・・−一−−−
−−・・〜・(wt%)
16.0%
7.5
4.0
2.0
0.3
適量
出*:p<f105.木本:p<0.01、故に8週間
麦ては5%、化1四置ではl九でガ恵左のり。c) Margins below this page] Electricity 1 Harm: Number of hairs removed at the time of the earthquake 1 Lie 0 [List the total of 3 times / t) Mi:: ” 1405/
Axis AOD (3) Examples of prescriptions for various other hair cosmetics are illustrated below. It goes without saying that the formulation is not limited to this example. (All compounding ratios in Examples are weight % (wt%). (A) Hair essence, ethanol, castor oil, horsetail extract, fragrance 1 pigment, purified water (wt%) 65.0% 5.0 1. 0 Appropriate amount total amount 100 (B) Hair shampoo sodium alkyl ether sulfate ------
-・・Ethanollauric acid jetanolamide・−・−Propylene glycol・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・· −・・−1−−−
--・・~・(wt%) 16.0% 7.5 4.0 2.0 0.3 Appropriate amount output*: p<f105. Kimoto: p<0.01, so 8 weeks barley is 5%, and 14th grade is l9 and Gae Sanori.
・精製水
全量100
(C)ヘアリンス (wt%)
・塩化ステアリルジメチル
ベンジルアンモニウム−・−・・−・−1,4%・エタ
ノールー−−−一−−−−・−−−−一・−・−・−一
一一一−−・・−・−・・・−7,5・ステアリルアル
コール・−申一・−・・−・−・・−0,6・グリセリ
ルモノステアレートー−−−−−1,5・スクワランー
・・・・・・・・・・・−・−・・−・・・・・−一−
−3、0・スギナ抽出物−・・−・−・−・−・=・−
・・−−−−−−−・−−−−−0,3・防腐剤・色素
・香料−・−−−−一−−−・−−−−−−−一−−適
量・精製水−・−・−・−一−−−−−−−−−−・−
・−−−−一−−−・−−一−−−−・−全量100(
D)ヘアトリートメント
・塩化ステアリルジメチル
ベンジルアンモニウム・−・−・−・・・・エタノール
・ステアリルアルコール−・・・−・・−・・・−・−
・−・−・グリセリルモノステアレート
・スクワラン
(wt %)
1.5%
10.0
4.0
3.0
10.0
・スギナ抽出物−・・・・−・・・−・−・・・−・・
−−−−−0,4・防腐剤・色素・香料・・・・・−−
−−−・・・・・−・・・−・・適量・精製水−・・・
〜・−・−・・・・・・・−・・・・−・・−・−・−
・−−−−全1100(E)整髪料
(a)(植物性)ポマード
・モクロウ
・ヒマシ油−・・・・・・−・・・・−・−・・・−・
・・・−・・・−・・・・ヒマワリ油
・硬化油
・スギナ抽出物−・・・・・・−・−・・−・・・・・
・・・−・−・香料
・色素、酸化防止剤−−−−−m−・−・−・−・・・
−−一−−(b)(鉱物性)ポマード
・ワセリン
・流動ハラフインー−一−−−−・−・−・・・−・・
・・・−・−・・ヒマワリ油
・パラフィン
・スギナ抽出物−・−・−・・・・・−・・−・・・・
−・(wt%)
10−13%
58〜53
0
2〜1
0.6
適量
通量
(賀t%)
39%
5
0
5
0.4
・香料−・−・−・・・・・・・・・−−−−−−m−
−−・・−・・・−−−m−・−・・適量・色素、酸化
防止剤・−・・・−−−−−・・−一−−−・−・適量
・香料
・精製水
適量
全量100
(C)ヘアクリーム(0/W型) (wt%
)・サラシミツロウ・−・・−・・−−−−−−−−−
−・・−−−−−−・ 3%・液状ラノリン−・−・・
・−・−・−・−・−−−一−・・−1・流動パラフィ
ン(355秒)−−−−−−−・・−30・ポリオキシ
エチレン
セチルエーテル(20E、O,)−・−・ 1.5・ポ
リオキシエチレン
セチルエーテル(5E、O,) −・−2,5・モノス
テアリン酸ソルビタン・・・ 1.5・エタノール−一
−−一−−・・・・−・ −・−7,5・スギナ抽出
物 ・・・・−一−−−−−−・・−0,3・バ
ラオキシ安息香酸
プロピル−・−・−・−−・−・−・−・適量・パラオ
キシ安息香酸メチルー−−−−−−一適量・ホウ砂−−
−−−−・−・・・−・−・・・・・−・・・・・−・
・−・−・−・ 0.3・エデト酸四ナトリウム・・・
・−・−・−・・適量・フロピレンゲリコール・−・−
−−一−−−−−・〜・−3(ゆヘアリキッド
(wt%)・ポリオキシプロピレン
ブチルエーテル ・−・−・−15〜25%・エタ
ノール−・−−−−一−・−・・−・〜・・−m−−−
・−・−・−・−50〜40・スギナ抽出物−−−−−
一−−−−−−・・−・−・・−一一一〜−・−0,4
・エデト酸二ナトリウムー−−−−一−−一−−・・・
・−・適量・香料1色素−・−・−・−・−−−−一・
−・・−一−−−−・・−・−適量・精製水・・
・・・・・・−・−−−−−・−・・−・−全量100
(e)セットローション
・ポリビニルピロリドン−・・−・・−・ポリオキシエ
チレン
コレステロール(24E、0.)・−・・・−・エタノ
ール
・グリセリン
・スギナ抽出物−・・・・・−・・・・・・−・−・−
・・・・−・−一−−−・・・香料1色素
(wt%)
2%
37.5
0.3
適量
・パラオキシ
安息香酸エステル−・−・−・・−・・−通量・精製水
−−−−−・−・・−・・・・−−−一−・−・・・−
・−・・−・・・−全量io。・Purified water total amount 100 (C) Hair rinse (wt%)
・Stearyldimethylbenzyl ammonium chloride--------1,4%--Ethanol------------------------------------ −・・・−7,5 Stearyl alcohol・−Shinichi・−・・−・−・・−0,6 Glyceryl monostearate−−−−1,5 Squalane−・・・・・・−・−・・−・・・・・−1−
−3,0・Equisetum extract−・・−・−・−・−・=・−
・ ・ -----------0, 3 ・ Preservatory, pigment / fragrance - ・ 一 — 1 ---------------------------------------- −・−・−・−1−−−−−−−−−−・−
・----1-----・--1-----・-Total amount 100 (
D) Hair treatment・Stearyldimethylbenzyl ammonium chloride・・・−・−・・Ethanol・Stearyl alcohol・・・・・・・・・・−
・−・−・Glyceryl monostearate/squalane (wt %) 1.5% 10.0 4.0 3.0 10.0 ・Horsetail extract−・・−・−・−・・−・・
−−−−−0,4・Preservatives・Pigments・Fragrance・・・・・−−
−−−・・・−・・・−・・Appropriate amount/Purified water−・・
〜・−・−・・・・・−・・−・・−・−・−
・---Total 1100 (E) Hair conditioner (a) (vegetable) Pomade, Japanese oak, castor oil-------------------
・・・−・・・−・・Sunflower oil, hydrogenated oil, horsetail extract −・・・・・・・−・−・・−・・・・・・・
・・・−・−・Fragrances, pigments, antioxidants−−−−−m−・−・−・−・・
−−1−−(b) (Mineral) Pomade/Vaseline/Fluid Halafine−−1−−−−・−・−・・・−・・
・・・−・−・・Sunflower oil, paraffin, horsetail extract−・−・−・・・・・−・・−・・
-・(wt%) 10-13% 58-53 0 2-1 0.6 Appropriate amount (gt%) 39% 5 0 5 0.4 ・Fragrance-・-・-・・・・・・・・・・...------m-
−−・・−・−−−m−・−・・Appropriate amount・Pigment, antioxidant・−・−−−−−・−1−−−・−・Appropriate amount・Fragrance・Purified water Appropriate amount Total amount 100 (C) Hair cream (0/W type) (wt%
)・White beeswax・−・・−・・−−−−−−−−−
−・・−−−−−−・3%・Liquid lanolin−・−・・
・−・−・−・−・−−−1−・・−1・Liquid paraffin (355 seconds)−−−−−−−−30・Polyoxyethylene cetyl ether (20E, O,)−・-・1.5・Polyoxyethylene cetyl ether (5E, O,) −・−2,5・Sorbitan monostearate... 1.5・Ethanol-1−−1−−・・−・−・-7,5・Horsetail extract・・・・−1−−−−−−・・−0,3・Propyl roseoxybenzoate−・−・−・−−・−・−・−・Adequate amount・Paraoxy Methyl benzoate --- Appropriate amount/Borax ---
−−−−・−・−・−・・・−・・・・・・・−・
・−・−・−・ 0.3・Tetrasodium edetate・・・
・−・−・−・・Adequate amount・Flopylene gelicol・−・−
−−1−−−−−・〜・−3 (Yu Hair Liquid
(wt%)・Polyoxypropylene butyl ether・−・−・−15 to 25%・Ethanol−・−−−−−・−・・−・〜・・−m−−−
・−・−・−・−50~40・Horsetail extract---
1-----・・−・−・・−111〜−・−0,4
・Edetate disodium---1---1---...
・−・Appropriate amount・Fragrance 1 pigment−・−・−・−・−−−−1・
−・・−1−−−−・・−・−Appropriate amount・Purified water・・
・・・・・・−・−−−−−・−・・−・−Total amount 100
(e) Set lotion, polyvinylpyrrolidone, polyoxyethylene cholesterol (24E, 0.), ethanol, glycerin, horsetail extract, etc.・・・-・-・-
・・−・−1−−−・・Fragrance 1 Dye (wt%) 2% 37.5 0.3 Appropriate amount・Paraoxybenzoic acid ester−・−・−・・−・・・Quantity・Purification Water-----・−・・−・・・・−−−1−・−・・・・−
・−・・−・・・−Total amount io.
げ)レジン質透明ゲル
・カルボキシ
(wt%)
(濁ヘアソリッド (wt%)・
流動バラフィンー−−一一一・・・・・・−−−−−一
・−・・−−−−−・−5,0%・エタノール−一−−
一・−・−−−−−一・・・・・−・−・−・・−・−
・・−・5.0・ラノリンアルコール・−−−一−−・
・−−−−m−−・−・−−−−−2,トラウリン酸
ジェタノールアミド−・−−−一−−・・−・−・・2
.0・ポリオキシエチレン
ラウリルエーテルリン酸・・・−・・−・7.0・スギ
ナ抽出物・−・−・・・−・・−・・−・・−・・・・
−−−−−−・0.2・精製水−・・−−一−−−・−
・・・−・−・・・・−一−−−・・・−−−〜−=−
−−−〜・−全量100く効果〉
この発明は、スギナ抽出物が有する毛根に栄養を与え、
特に頭髪などの体毛の成長を促進して成長期から休止期
に入る退行速度を遅延し且つ休止期突入を防止すること
による脱毛防止作用および毛根の萎縮現象を防止するこ
とによる顕著な脱毛防止作用に基づき、極めて優れた休
止刈上性脱毛の防止および成長刈上性脱毛の防止を図る
ことができ、広範囲の各種脱毛症に対して卓越した脱毛
防止効果がある等、発明の目的を達成する顕著な効果を
奏する。hair) Resin transparent gel carboxy (wt%) (turbid hair solid (wt%)
Liquid paraffin--111...-------1-----5,0% ethanol-1--
1・−・−−−−−1・・・・−・−・−・・−・−
・・-・5.0・Lanolin alcohol・−−1−−・
・−−−m−−・−・−−−−−2, tlauric acid jetanolamide−−−−1−−・・−・−・2
.. 0. Polyoxyethylene lauryl ether phosphoric acid...--7.0. Horsetail extract------------------...
−−−−−−・0.2・Purified water−・・−−1−−−・−
・・・−・−・・−1−−−・・・−−−〜−=−
---~・-100% effect in total> This invention provides nutrition to the hair roots of horsetail extract,
In particular, it promotes the growth of body hair such as scalp hair, delays the rate of degeneration from the growth phase to the telogen phase, and prevents the entry into the telogen phase, and has a remarkable hair loss prevention effect by preventing hair root atrophy. Based on this, it is possible to achieve extremely excellent prevention of quiescent hair loss and growth hair loss, and to achieve the purpose of the invention, such as having an outstanding hair loss prevention effect on a wide variety of alopecias. It has a remarkable effect.
しかも、この発明にかかる脱毛防止剤は、脱毛症状のな
い正常のヒトの毛髪には全く悪影響を与えることがなく
その毛髪の正常な状態を維持するという優れた作用効果
を併せ有し、しかも副作用もない等々、発明の目的を達
成する顕著な効果を奏する。Moreover, the anti-hair loss agent according to the present invention has an excellent action and effect of maintaining the normal state of hair without any adverse effect on normal human hair without any symptoms of hair loss, and also has side effects. The present invention has a remarkable effect of achieving the object of the invention.
Claims (1)
を含むことを特徴とする脱毛防止剤。(1) A hair loss prevention agent characterized by containing horsetail extract as an active ingredient for hair loss prevention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003239A JPH03209309A (en) | 1990-01-10 | 1990-01-10 | Alopecia-preventing agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003239A JPH03209309A (en) | 1990-01-10 | 1990-01-10 | Alopecia-preventing agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH03209309A true JPH03209309A (en) | 1991-09-12 |
Family
ID=11551906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003239A Pending JPH03209309A (en) | 1990-01-10 | 1990-01-10 | Alopecia-preventing agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH03209309A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10265349A (en) * | 1997-03-26 | 1998-10-06 | Shiseido Co Ltd | Hair restorer |
| JPH11124318A (en) * | 1997-10-17 | 1999-05-11 | Kao Corp | Anti-white hair agent |
| JP2002316917A (en) * | 2001-04-19 | 2002-10-31 | Naris Cosmetics Co Ltd | Hair tonic/hair growing agent, gray hair improving cosmetic |
| JP2003061617A (en) * | 2001-08-30 | 2003-03-04 | Univ Nihon | Health food with antiallergic action |
| JP2005068159A (en) * | 2004-11-01 | 2005-03-17 | Kao Corp | Gray hair prevention agent |
| WO2006058430A1 (en) * | 2004-12-02 | 2006-06-08 | Testa Hair Holdings Inc. | Composition for treating hair and scalp and method for preparing same |
| ITRM20130632A1 (en) * | 2013-11-17 | 2015-05-18 | Naples Hair Di Costantino Antonino | PROCEDURE TO OBTAIN A LOTION WITH EQUISETO EXTRACT FOR HAIR GROWTH AND SO LOTION OBTAINED |
| JP2020094035A (en) * | 2018-11-30 | 2020-06-18 | 株式会社マンダム | Solid hairdressing composition |
-
1990
- 1990-01-10 JP JP2003239A patent/JPH03209309A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10265349A (en) * | 1997-03-26 | 1998-10-06 | Shiseido Co Ltd | Hair restorer |
| JPH11124318A (en) * | 1997-10-17 | 1999-05-11 | Kao Corp | Anti-white hair agent |
| JP2002316917A (en) * | 2001-04-19 | 2002-10-31 | Naris Cosmetics Co Ltd | Hair tonic/hair growing agent, gray hair improving cosmetic |
| JP2003061617A (en) * | 2001-08-30 | 2003-03-04 | Univ Nihon | Health food with antiallergic action |
| JP2005068159A (en) * | 2004-11-01 | 2005-03-17 | Kao Corp | Gray hair prevention agent |
| WO2006058430A1 (en) * | 2004-12-02 | 2006-06-08 | Testa Hair Holdings Inc. | Composition for treating hair and scalp and method for preparing same |
| ITRM20130632A1 (en) * | 2013-11-17 | 2015-05-18 | Naples Hair Di Costantino Antonino | PROCEDURE TO OBTAIN A LOTION WITH EQUISETO EXTRACT FOR HAIR GROWTH AND SO LOTION OBTAINED |
| JP2020094035A (en) * | 2018-11-30 | 2020-06-18 | 株式会社マンダム | Solid hairdressing composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0660698B1 (en) | Cosmetic or dermatologic composition containing at least one saponine of the ginsenoside type, and its applications particularly to hair care | |
| BRPI0808065A2 (en) | NEW COSMETIC AND / OR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS | |
| CA2139253C (en) | Skin external agent | |
| JP3611128B2 (en) | Testosterone-5-α-reductase inhibitor | |
| KR102369387B1 (en) | Cosmetic Composition for prevention of depilation or improvement of hair growth | |
| JPH03188019A (en) | Testosterone-5alpha-reductase inhibitor | |
| KR102175249B1 (en) | Composition for improving condition of hair and scalp containing Panax ginseng extract and Green tea extract | |
| JPH05255044A (en) | Hair grower | |
| JPS63115807A (en) | Cosmetic | |
| JPS6293217A (en) | Hair tonic | |
| KR20210083236A (en) | Composition for preventing hair loss and improving the scalp | |
| JPH0853327A (en) | Hair nourishing and hair-restoring agents using allantoin or its derivatives | |
| JPH05310537A (en) | Hair tonic | |
| CN118477021A (en) | Anti-hair loss and anti-itching shampoo containing plant extracts and preparation method thereof | |
| KR100331675B1 (en) | External skin preparation | |
| JPH1045559A (en) | Cosmetic | |
| JPH11302133A (en) | Cosmetic for scalp and hair | |
| KR20040056079A (en) | Cosmetic composition for preventing and therapeutic for a pimple | |
| JP3542700B2 (en) | Head composition | |
| KR0154210B1 (en) | Hair cosmetic composition | |
| JP7766360B2 (en) | Filaggrin mRNA expression promoter | |
| JPS63313715A (en) | Hair growth stimulating composition | |
| JP2013144651A (en) | Keratin production promoter, food, skin external preparation, and hair restorer | |
| KR100583158B1 (en) | Hair growth promoter containing Astragalus extract as an active ingredient | |
| JP2811481B2 (en) | Hair restoration |